At the news
? BULLISHIMPACT 4/10 COURT-RULING filed Jul 14, 2026 at 20:00 ET
Corcept won a limited discovery ruling in its antitrust defense against Teva Pharmaceuticals. The court granted Corcept permission to depose Teva's CEO Richard Francis for up to 2 hours regarding his critique of Teva's mifepristone strategy, but denied Corcept's broader requests to depose him on pricing/distribution and to collect his custodial documents. This is a modest procedural victory for Corcept, it gains some ammunition to argue Teva's generic mifepristone failed due to Teva's own choices, not Corcept's conduct, but the substance of the underlying antitrust case remains unresolved.
- Court granted Corcept permission to depose Teva CEO Richard Francis for up to 2 hours on his critique of Teva's mifepristone strategy and possible solutions
- Court denied Corcept's requests to depose Francis on pricing, distribution strategy, and to collect his custodial documents
- The ruling does not resolve the underlying antitrust claims; it is a discovery-level procedural order
- No damages were awarded, no injunction issued, and the case continues
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access